6 March 2023

Bellevue Healthcare Trust plc (the "Company")

LEI: 213800HQ3J3H9YF2UI82

Publication of Circular - Scrip Dividend Scheme

The Board of Bellevue Healthcare Trust plc today announced that a final dividend of 3.235p per Ordinary Share has been declared in respect of the year ended 30 November 2022 (the "Final Dividend") and that Shareholders would be offered the opportunity to elect for their cash dividend to be automatically subscribed on their behalf for new Ordinary Shares (the "Scrip Dividend Scheme"). Accordingly, the Company has today posted to Shareholders a circular setting out details of the Scrip Dividend Scheme (the "Circular").

Certificated Shareholders who have already joined the Scrip Dividend Scheme by providing an instruction through the Registrar's website at www.signalshares.com and wish to continue to have the full amount of cash dividends, including the Final Dividend, automatically subscribed for New Shares, do not need to take any further action.

Certificated Shareholders who have not yet joined the Scrip Dividend Scheme and who wish to elect for the scrip dividend alternative can do so online at https://www.signalshares.com or a mandate form can be obtained by contacting the Company's registrar, Link Group on 0371 664 0321*.

Uncertificated Shareholders can make an election via the CREST system. 

Shareholders who do not elect to participate in the Scrip Dividend Scheme will receive their dividends simply in cash.

If qualifying Shareholders wish to elect to participate in the scrip dividend alternative in relation to the Final Dividend their instruction, mandate form, or CREST election (as applicable) must be received by Link Group by no later than 5.00 p.m. on 31 March 2023

The price by reference to which a Shareholder's cash dividend will be used to subscribe for New Shares will be the unaudited Net Asset Value per Ordinary Share as at close of business on 31 March 2023, which will be published on 3 April 2023.

The Directors believe that the offer of the Scrip Dividend Scheme may be advantageous to Shareholders because it enables Shareholders to increase their shareholding in the Company in a simple manner without paying dealing costs. The Directors also believe that the offer of the Scrip Dividend Scheme may be advantageous to the Company (and therefore to the Shareholders in general) since the relevant cash dividend amounts payable to Shareholders who have elected to participate in the Scrip Dividend Scheme are reinvested in the Company as additional share capital. However, the decision whether to elect for the Scrip Dividend Scheme will depend on a Shareholder's own circumstances. Shareholders are encouraged to review the full terms and conditions of the Scrip Dividend Scheme and the election procedure for certificated and uncertificated Shareholders set out in the Circular.

The Circular is available on the Company's website https://www.bellevuehealthcaretrust.com  and has also been submitted to the Financial Conduct Authority and will be available for inspection through the NSM (https://data.fca.org.uk/#/nsm/nationalstoragemechanism).

Capitalised terms not otherwise defined in this announcement have the meanings given in the Circular.

*Calls are charged at the standard geographic rate and will vary by provider.  Calls outside the United Kingdom will be charged at the applicable international rate.  The helpline is open between 9.00 a.m. - 5.30 p.m., Monday to Friday excluding public holidays in England and Wales.

The distribution of the Circular in certain jurisdictions (including the United States of America, Canada, Japan, South Africa or Australia or their respective territories or possessions) other than the United Kingdom may be restricted by law. Accordingly, the Circular may not be distributed or published in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons into whose possession the Circular comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Enquiries:

Apex Listed Companies Services (UK) Limited                     020 3327 9720